Drug Therapies and the Risk of Malignancy in Crohn's Disease: Results From the TREAT™ Registry

Abstract

In the TREAT Registry, age, disease duration, and smoking were independently associated with increased risk of malignancy. Although results for immunosuppressant use were equivocal, no significant association between malignancy and infliximab was observed.